Vendor comparison · 2026
Rapamycin (Sirolimus) vendors: 0 compared on COAs and price
OtherAlso known as Sirolimus
Evidence tier
Substantial published literature
12,874 publications over 51 years · trials not yet curated
- Vendors carrying it
- 0
- 0 with a listed price
- Vendors with checkable COAs
- 0
- 0 publish any certificate
- Lots tested
- 0
- 0 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- —
- Laboratories named
- 0
- Median label gap
- —
- Median purity
- —
- Lowest price per mg
- —
- Publications located
- 13k
- researched since 1975
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
No indexed vendor publishes a Rapamycin (Sirolimus) certificate naming a laboratory this index could check, so no vendor can be called well-tested for it yet. No vendor price for Rapamycin (Sirolimus) is on record. 0 vendors carrying Rapamycin (Sirolimus) are compared below. 0 publish at least one certificate naming a checkable laboratory, no lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Rapamycin (Sirolimus)
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| No indexed vendor currently lists this compound. | |||||||||
Independent assays
No independently commissioned assay of Rapamycin (Sirolimus) is on file. No certificate for it has been indexed at all. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
Laboratories used
No certificate for Rapamycin (Sirolimus) names a laboratory this index could identify.
Every certificate record
No certificate record for Rapamycin (Sirolimus) is indexed. Either no vendor publishes one, or those published could not be read without an account.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1975 — 51 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
12,874 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
No vendor testing policy recorded yet — nothing recorded yet
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Rapamycin (Sirolimus)?
Rapamycin (sirolimus), a macrolide inhibitor of the mTOR pathway. It is an approved prescription medicine and one of the most-studied compounds in ageing and longevity research.
Studied in published research for ageing and longevity, as an mTOR inhibitor.
Regulatory status
Sirolimus is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial — JAMA dermatology (2021)
Peer-reviewed article indexed in PubMed, published in JAMA dermatology (2021).
- Rapamycin (sirolimus, rapamune) — Current opinion in nephrology and hypertension (1995)
Peer-reviewed article indexed in PubMed, published in Current opinion in nephrology and hypertension (1995).
- Sirolimus — PubMed-indexed journal (2012)
Peer-reviewed article indexed in PubMed, published in PubMed-indexed journal (2012).
- Sirolimus — PubMed-indexed journal (2006)
Peer-reviewed article indexed in PubMed, published in PubMed-indexed journal (2006).
- Sirolimus — American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2022)
Peer-reviewed article indexed in PubMed, published in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2022).
- Rapamycin (sirolimus): a two-edged sword? — Journal of molecular and cellular cardiology (2006)
Peer-reviewed article indexed in PubMed, published in Journal of molecular and cellular cardiology (2006).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.